All In Biotech

Drug Trial Radar · NCT05425745

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

354

Actual

Start

Jul 25, 2022

Primary completion

May 28, 2024

Study completion May 28, 2024

Sponsor

Lead sponsor
NewAmsterdam PharmaIndustry
Sponsor type
Industry
First posted
Jun 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia (HeFH).

Conditions

  • Dyslipidemias
  • High Cholesterol
  • Hypercholesterolemia
  • Familial Hypercholesterolemia
  • Lipid Metabolism Disorder
  • Metabolic Disease
  • Lipid Metabolism, Inborn Errors
  • Genetic Disease, Inborn
  • Hyperlipoproteinemias

Interventions

  • ObicetrapibDrug

    10 mg Obicetrapib tablet

  • PlaceboDrug

    placebo tablet made to resemble active

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]Time frame: 84 Days

Locations

96 sites in 10 countries. Site status is shown where the registry gives one.

  • Site 01022

    Jonesboro, Arkansas

  • Site 01015

    Toluca Lake, California

  • Site 01009

    Sarasota, Florida

  • Site 01023

    Boise, Idaho

  • Site 01018

    Chicago, Illinois

  • Site 01012

    Iowa City, Iowa

  • Site 01007

    Baton Rouge, Louisiana

  • Site 01005

    Port Gibson, Mississippi

  • Site 01006

    St Louis, Missouri

  • Site 01011

    Lincoln, Nebraska

  • Site 01004

    Norfolk, Nebraska

  • Site 01002

    Morristown, New Jersey

  • Site 01010

    New Providence, New Jersey

  • Site 01001

    North Massapequa, New York

  • Site 01020

    Morganton, North Carolina

  • Site 01019

    Winston-Salem, North Carolina

  • Site 01008

    Chattanooga, Tennessee

  • Site 01016

    El Paso, Texas

  • Site 01013

    Houston, Texas

  • Site 01014

    Suffolk, Virginia

  • Site 06007

    Brampton, Canada

  • Site 06008

    Chicoutimi, Canada

  • Site 06005

    Halifax, Canada

  • Site 06003

    Montreal, Canada

  • Site 06009

    Montreal, Canada

  • Site 06004

    Québec, Canada

  • Site 06006

    Sherbrooke, Canada

  • Site 06001

    Vancouver, Canada

  • Site 06002

    Victoria, Canada

  • Site 02006

    Brno, Czechia

  • Site 02002

    Hradec Králové, Czechia

  • Site 02003

    Prague, Czechia

  • Site 02005

    Prague, Czechia

  • Site 02004

    Prague, Czechia

  • Site 02001

    Uherské Hradiště, Czechia

  • Site 022001

    Batumi, Georgia

  • Site 022003

    Tbilisi, Georgia

  • Site 022004

    Tbilisi, Georgia

  • Site 022010

    Tbilisi, Georgia

  • Site 022006

    Tbilisi, Georgia

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.